Brief: Revive Therapeutics Announces Results Of Phase 3 Clinical Study For Bucillamine In The Treatment Of COVID-19

Revive Therapeutics

06/07/2023 11:44

July 6 (Reuters) - Revive Therapeutics Ltd  RVV.CD :
    * REVIVE THERAPEUTICS ANNOUNCES RESULTS OF PHASE 3 CLINICAL
STUDY
FOR BUCILLAMINE IN THE TREATMENT OF COVID-19
    * REVIVE THERAPEUTICS ANNOUNCES RESULTS OF PHASE 3 CLINICAL
STUDY
FOR BUCILLAMINE IN THE TREATMENT OF COVID-19
    * REVIVE THERAPEUTICS LTD - STUDY DID NOT ACHIEVE
STATISTICAL
SIGNIFICANCE ON CLINICAL ENDPOINTS
    * REVIVE THERAPEUTICS LTD - COMMITTED TO ADVANCING CLINICAL
AND
COMMERCIAL DEVELOPMENT OF BUCILLAMINE
    * REVIVE THERAPEUTICS LTD - REFORMULATING BUCILLAMINE IN AN
INTRAVENOUS AND INHALED VERSION
    * REVIVE THERAPEUTICS: NO ASSURANCE THAT CO WILL PROCEED
WITH
CLINICAL DEVELOPMENT, APPROVALS OF BUCILLAMINE FOR COVID-19 IN
U.S. & INTERNATIONALLY
    * REVIVE THERAPEUTICS - TO SEEK POTENTIAL FUNDING
OPPORTUNITIES
INCLUDING FROM BARDA, ASPR AT U.S. DEPARTMENT OF HEALTH AND
HUMAN SERVICES

Source text for Eikon:  ID:nGNXbBG4cW 
Further company coverage:  RVV.CD 

 (Reuters.Briefs@thomsonreuters.com)